Reduction in early mortality on antiretroviral therapy for adults in rural south africa since change in CD4+ cell count eligibility criteria

Journal of Acquired Immune Deficiency Syndromes

Volumn 65, Issue 1, 2014, Pages

  Lessells, Richard J ^a,b   Mutevedzi, Portia C ^a,c   Iwuji, Collins C ^a,d   Newell, Marie Louise ^a,e  

^a UNIVERSITY OF KWAZULU NATAL   (South Africa)

^b LONDON SCHOOL OF HYGIENE AND TROPICAL MEDICINE   (United Kingdom)

^c UNIVERSITY COLLEGE LONDON   (United Kingdom)

^d BRIGHTON AND SUSSEX MEDICAL SCHOOL   (United Kingdom)

^e UNIVERSITY COLLEGE LONDON   (United Kingdom)

Author keywords

Access to health care; Antiretroviral agents; CD4 lymphocyte count; HIV 1; Mortality

Indexed keywords

ANTIRETROVIRUS AGENT;

ADULT; AGE; ARTICLE; CD4 LYMPHOCYTE COUNT; DEATH; FEMALE; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MAJOR CLINICAL STUDY; MALE; MORTALITY; PRIORITY JOURNAL; RISK ASSESSMENT; SEX DIFFERENCE; SOUTH AFRICA; TUBERCULOSIS;

ADULT; AGE FACTORS; ANTI-HIV AGENTS; CD4 LYMPHOCYTE COUNT; ELIGIBILITY DETERMINATION; FEMALE; HIV INFECTIONS; HUMANS; MALE; RISK FACTORS; RURAL POPULATION; SEX FACTORS; SOUTH AFRICA;

EID: 84893773103     PISSN: 15254135     EISSN: 10779450     Source Type: Journal    
DOI: 10.1097/QAI.0b013e31829ceb14     Document Type: Article

References (41)

1. Joint United Nations Programme on HIV/AIDS. Together We Will End AIDS. Geneva, Switzerland: UNAIDS; 2012. Available at: http://www.unaids.org/en/media/ unaids/contentassets/documents/epidemiology/2012/20120718-togetherwewillendaids- en.pdf. Accessed September 3, 2012.
2. Boulle A, Bock P, Osler M, et al. Antiretroviral therapy and early mortality in South Africa. Bull World Health Organ. 2008;86:678-687.
3. Lawn SD, Harries AD, Anglaret X, et al. Early mortality among adults accessing antiretroviral treatment programmes in sub-Saharan Africa. AIDS. 2008;22:1897-1908.
4. Mutevedzi PC, Lessells RJ, Heller T, et al. Scale-up of a decentralized HIV treatment programme in rural KwaZulu-Natal, South Africa: does rapid expansion affect patient outcomes? Bull World Health Organ. 2010;88:593-600.
5. Braitstein P, Brinkhof MW, Dabis F, et al. Mortality of HIV-1-infected patients in the first year of antiretroviral therapy: comparison between low-income and high-income countries. Lancet. 2006;367:817-824.
6. Siegfried N, Uthman OA, Rutherford GW. Optimal time for initiation of antiretroviral therapy in asymptomatic, HIV-infected, treatment-naive adults. Cochrane Database Syst Rev. 2010;3:CD008272.
7. Severe P, Juste MA, Ambroise A, et al. Early versus standard antiretroviral therapy for HIV-infected adults in Haiti. N Engl J Med. 2010;363: 257-265.
8. World Health Organization. Antiretroviral Therapy for HIV Infection in Adults and Adolescents: Recommendations for a Public Health Approach-2010 Revision. Geneva, Switzerland: WHO; 2010.
9. South African National AIDS Council. Statement on the meeting of the South African National AIDS Council. 2011; Available at: http://www.sanac.org. za/files/uploaded/886-Plenary%20Press%20Statement% 2012Aug11.pdf. Accessed September 3, 2012.
10. Ford N, Kranzer K, Hilderbrand K, et al. Early initiation of antiretroviral therapy and associated reduction in mortality, morbidity and defaulting in a nurse-managed, community cohort in Lesotho. AIDS. 2010;24:2645-2650.
11. Vandenbroucke JP, von Elm E, Altman DG, et al. Strengthening the Reporting of Observational Studies in Epidemiology (STROBE): explanation and elaboration. PLoS Med. 2007;4:e297.
12. von Elm E, Altman DG, Egger M, et al. The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies. PLoS Med. 2007;4:e296.
13. Houlihan CF, Bland RM, Mutevedzi PC, et al. Cohort profile: Hlabisa HIV treatment and care programme. Int J Epidemiol. 2011;40:318-326.
14. Department of Health. National Antiretroviral Treatment Guidelines. Pretoria, South Africa: Department of Health; 2004.
15. Department of Health. Clinical Guidelines for the Management of HIV & AIDS in Adults and Adolescents. Pretoria, South Africa: Department of Health; 2010.
16. Tanser F, Hosegood V, Barnighausen T, et al. Cohort Profile: Africa Centre Demographic Information System (ACDIS) and population-based HIV survey. Int J Epidemiol. 2008;37:956-962.
17. Lessells RJ, Mutevedzi PC, Cooke GS, et al. Retention in HIV care for individuals not yet eligible for antiretroviral therapy: rural KwaZulu-Natal, South Africa. J Acquir Immune Defic Syndr. 2011;56:e79-e86.
18. Mutevedzi PC, Lessells RJ, Rodger AJ, et al. Association of age with mortality and virological and immunological response to antiretroviral therapy in rural South African adults. PLoS One. 2011;6:e21795.
19. Bakoyannis G, Touloumi G, on behalf of CASCADE collaboration. A practical guide on modelling competing risk data. 2008; Available at: http://www.ctu.mrc.ac.uk/cascade/content-pages/documents-and-files/ Comp-Risks-guide.pdf. Accessed September 3, 2012.
20. Gutierrez R. Competing-risks regression. 2010; Available at: http://www.stata. com/meeting/boston10/boston10-gutierrez.pdf. Accessed September 3, 2012.
21. Mutevedzi PC, Lessells RJ, Newell ML. What happens to patients lost during antiretroviral therapy in rural South Africa? Paper presented at: 15th International Workshop on HIV Operational Databases; March 24-26, 2011; Prague, Czech Republic.
22. Braitstein P, Boulle A, Nash D, et al. Gender and the use of antiretroviral treatment in resource-constrained settings: findings from a multicenter collaboration. J Womens Health (Larchmt). 2008;17:47-55.
23. Cornell M, Schomaker M, Garone DB, et al. Gender differences in survival among adult patients starting antiretroviral therapy in South Africa: a Multicentre Cohort Study. PLoS Med. 2012;9:e1001304.
24. Herbst AJ, Cooke GS, Barnighausen T, et al. Adult mortality and antiretroviral treatment roll-out in rural KwaZulu-Natal, South Africa. Bull World Health Organ. 2009;87:754-762.
25. Herbst AJ, Mafojane T, Newell ML. Verbal autopsy-based cause-specific mortality trends in rural KwaZulu-Natal, South Africa, 2000-2009. Popul Health Metr. 2011;9:47.
26. Bradshaw D, Dorrington RE, Laubscher R. Rapid Mortality Surveillance Report 2011. Cape Town, South Africa: South African Medical Research Council; 2012.
27. Bor J, Herbst AJ, Newell ML, et al. Increases in adult life expectancy in rural South Africa: valuing the scale-up of HIV treatment. Science. 2013; 339:961-965.
28. May M, Boulle A, Phiri S, et al. Prognosis of patients with HIV-1 infection starting antiretroviral therapy in sub-Saharan Africa: a collaborative analysis of scale-up programmes. Lancet. 2010;376(9739):449-457.
29. Boulle A, Van Cutsem G, Hilderbrand K, et al. Seven-year experience of a primary care antiretroviral treatment programme in Khayelitsha, South Africa. AIDS. 2010;24:563-572.
30. Fox MP, Shearer K, Maskew M, et al. Treatment outcomes after 7 years of public-sector HIV treatment. AIDS. 2012;26:1823-1828.
31. Nglazi MD, Lawn SD, Kaplan R, et al. Changes in programmatic outcomes during 7 years of scale-up at a community-based antiretroviral treatment service in South Africa. J Acquir Immune Defic Syndr. 2011;56:e1-e8.
32. Houlihan CF, Mutevedzi PC, Lessells RJ, et al. The tuberculosis challenge in a rural South African HIV programme. BMC Infect Dis. 2010;10:23.
33. Lessells RJ, Mutevedzi PC, Ndirangu J, et al. Contribution of TB and drugresistant TB to early mortality on antiretroviral therapy in rural KwaZulu-Natal: prospective cohort study. Paper presented at: 5th South African TB Conference; June 12-15, 2012; Durban, South Africa [abstract 140].
34. Lawn SD, Harries AD, Meintjes G, et al. Reducing deaths from tuberculosis in antiretroviral treatment programmes in sub-Saharan Africa. AIDS. 2012;26:2121-2133.
35. Lawn SD, Myer L, Edwards D, et al. Short-term and long-term risk of tuberculosis associated with CD4 cell recovery during antiretroviral therapy in South Africa. AIDS. 2009;23:1717-1725.
36. Abdool Karim SS, Naidoo K, Grobler A, et al. Timing of initiation of antiretroviral drugs during tuberculosis therapy. N Engl J Med. 2010;362: 697-706.
37. Abdool Karim SS, Naidoo K, Grobler A, et al. Integration of antiretroviral therapy with tuberculosis treatment. N Engl J Med. 2011;365:1492-1501.
38. Murphy RA, Sunpath H, Kuritzkes DR, et al. Antiretroviral therapyassociated toxicities in the resource-poor world: the challenge of a limited formulary. J Infect Dis. 2007;196(suppl 3):S449-S456.
39. Maheswaran H, Thulare H, Stanistreet D, et al. Starting a home and mobile HIV testing service in a rural area of South Africa. J Acquir Immune Defic Syndr. 2012;59:e43-e46.
40. Gupta S, Granich R, Suthar AB, et al. Global policy review of antiretroviral therapy eligibility criteria for treatment and Prevention of HIV and tuberculosis in adults, pregnant women, and Serodiscordant Couples. J Acquir Immune Defic Syndr. 2013;62:e87-e97. 10.1097/QAI. 1090b1013e31827e34992.
41. Cornell M, Technau K, Fairall L, et al. Monitoring the South African national antiretroviral treatment programme, 2003-2007: the IeDEA Southern Africa collaboration. S Afr Med J. 2009;99:653-660.